218 related articles for article (PubMed ID: 34454906)
1. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
3. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
4. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
5. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
7. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
10. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
Li J; Liu L; Feng Z; Wang X; Huang Y; Dai H; Zhang L; Song F; Wang D; Zhang P; Ma B; Li H; Zheng H; Song F; Chen K
Breast Cancer; 2020 Jul; 27(4):621-630. PubMed ID: 32040723
[TBL] [Abstract][Full Text] [Related]
12. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
13. Serum CA724 has no diagnostic value for gastrointestinal tumors.
Cao H; Zhu L; Li L; Wang W; Niu X
Clin Exp Med; 2023 Oct; 23(6):2433-2442. PubMed ID: 36920593
[TBL] [Abstract][Full Text] [Related]
14. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer.
Chen R; Jiang C; Zhu Q; You S; Li Y; Li S; Ding L; Meng H; Yang Y; Zha X; Wang J
Medicine (Baltimore); 2020 Jul; 99(29):e21231. PubMed ID: 32702897
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
16. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
[TBL] [Abstract][Full Text] [Related]
18. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
19. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
20. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
